New Use for Methotrexate in Spondyloarthritis?
eMediNexus, 22 January 2020
remove_red_eye 596 Views
#Orthopedics #Pharmacist #Rheumatology
Coronavirus Live Count Map India
remove_red_eye 596 Views
COVID-19 Vaccine Updates
#Orthopedics #Pharmacist #Rheumatology
Adding methotrexate to adalimumab (Humira) in axial spondyloarthritis was associated with reduced immunogenicity, as shown by a lower rate of developing antidrug antibodies, French researchers reported.
In a group of 107 patients with spondyloarthritis, 25% of those given methotrexate along with adalimumab developed antidrug antibodies by week 26 compared with 47.3% of those who received adalimumab as monotherapy, for a relative risk of 0.53 (95% CI 0.31-0.91), reported Denis Mulleman, MD, PhD, of the University of Tours, and colleagues. The findings were published online in RMD Open: Rheumatic & Musculoskeletal Diseases.
To comment on this article,
create a free account.
Sign Up
to instantly read 30000+ free Articles & 1000+ Case Studies
Already registered?
.jpg)
